BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases
On Dec. 19, 2025, BioMarin Pharmaceutical and Amicus Therapeutics announced that BioMarin has entered into a definitive agreement…
Fabry disease